• 1. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 2. An interplay between electronic and structural effects on the photoluminescence decay mechanisms in LaPO4·nH2O:Tb3+ and LaPO4:Tb3+ single-crystal nanorods?
  M. T. Colomer,S. Díaz-Moreno,A. Tamayo,A. L. Ortiz J. Mater. Chem. C, 2018,6, 12643-12651
• 3. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 4. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 5. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535

Introduction to 4-Fluoro-N-methyl-3-nitrobenzamide (CAS No. 475216-25-2)

4-Fluoro-N-methyl-3-nitrobenzamide is a significant compound in the field of pharmaceutical chemistry, exhibiting a unique structural framework that has garnered considerable attention from researchers. This compound, identified by its CAS number 475216-25-2, is characterized by a benzamide core substituted with a fluoro group at the 4-position and a nitro group at the 3-position. The presence of these functional groups imparts distinct chemical properties, making it a valuable intermediate in the synthesis of various pharmacologically active molecules.

The benzamide moiety is a well-known pharmacophore in medicinal chemistry, often contributing to the bioactivity and binding affinity of drug candidates. The introduction of a fluoro substituent at the para position enhances the metabolic stability and lipophilicity of the molecule, which are critical factors in drug design. Additionally, the nitro group introduces a polar region that can interact favorably with biological targets, further influencing the compound's pharmacokinetic profile.

In recent years, there has been growing interest in the development of novel therapeutic agents targeting neurological disorders. The structural features of 4-Fluoro-N-methyl-3-nitrobenzamide make it a promising candidate for further investigation in this area. Studies have shown that benzamide derivatives can modulate neurotransmitter systems, potentially offering benefits in treating conditions such as depression, anxiety, and neurodegenerative diseases. The specific arrangement of the fluoro and nitro groups in this compound may enhance its interaction with relevant receptors or enzymes, thereby improving therapeutic efficacy.

The synthesis of 4-Fluoro-N-methyl-3-nitrobenzamide involves multi-step organic transformations, typically starting from commercially available precursors. The introduction of the fluoro group can be achieved through nucleophilic aromatic substitution or metal-catalyzed cross-coupling reactions, while the nitro group is commonly introduced via electrophilic aromatic substitution. The choice of synthetic route depends on factors such as yield, purity, and scalability, which are crucial for industrial applications.

Advances in computational chemistry have enabled researchers to predict the biological activity of 4-Fluoro-N-methyl-3-nitrobenzamide with greater accuracy. Molecular modeling techniques can simulate interactions between the compound and biological targets, providing insights into its mechanism of action. These predictions are invaluable for guiding experimental design and optimizing drug candidates for clinical development.

The pharmacological profile of 4-Fluoro-N-methyl-3-nitrobenzamide has been explored in several preclinical studies. Initial findings suggest that it exhibits moderate affinity for certain neurotransmitter receptors, indicating potential therapeutic effects. However, further research is needed to fully elucidate its pharmacodynamics and pharmacokinetics. In vitro studies have also demonstrated its ability to inhibit specific enzymes involved in disease pathways, reinforcing its potential as a lead compound for drug development.

The role of fluorine substituents in enhancing drug properties cannot be overstated. The presence of a fluorine atom can significantly improve metabolic stability by resisting hydrolysis and oxidation. This characteristic is particularly important for drugs that require longer half-lives to achieve therapeutic effects. Additionally, fluorine atoms can influence drug distribution and excretion, further modulating its overall pharmacokinetic profile.

Recent developments in synthetic methodologies have also contributed to the growing interest in 4-Fluoro-N-methyl-3-nitrobenzamide. New catalytic systems and green chemistry approaches have made it possible to synthesize this compound more efficiently and sustainably. These advancements not only reduce costs but also minimize environmental impact, aligning with global efforts towards sustainable pharmaceutical production.

The potential applications of 4-Fluoro-N-methyl-3-nitrobenzamide extend beyond neurological disorders. Preliminary data suggest that it may have applications in anti-inflammatory and anticancer therapies due to its ability to modulate key signaling pathways. Further investigation into these areas could uncover new therapeutic opportunities and expand its market potential.

In conclusion, 4-Fluoro-N-methyl-3-nitrobenzamide (CAS No. 475216-25-2) is a versatile compound with significant pharmaceutical potential. Its unique structural features and favorable chemical properties make it an attractive candidate for further research and development. As our understanding of its pharmacological effects grows, so too does its promise as a lead compound for novel therapeutics.

• 228425-41-0(Benzamide, N-(4-fluoro-3-nitrophenyl)-)
• 498539-19-8(Benzamide, N-(diphenylmethyl)-4-fluoro-3-nitro-)
• 349-02-0(4-Fluoro-3-nitrobenzamide)
• 4297-70-5(Succinamic acid, N-vinyl-, hydrazide (7CI,8CI))
• 658700-20-0(Benzamide, 3-fluoro-N-methyl-4-nitro-)
• 332116-19-5(N,N'-bis(2-fluorophenyl)-5-nitrobenzene-1,3-dicarboxamide)
• 330468-30-9(N,N'-bis(4-fluoro-3-nitrophenyl)benzene-1,3-dicarboxamide)
• 474018-94-5(N,N-Diethyl-4-fluoro-3-nitrobenzamide)
• 474020-75-2(N,N-Diethyl-3-fluoro-4-nitrobenzamide)
• 3556-52-3(3-fluoro-4-nitrobenzamide)